Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia

Published:2020-10-29 Issue:12 Volume:36 Page:2009-2018
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Huang Qing¹,Emond Bruno²,Lafeuille Marie-Hélène²,Gupta Deepshekhar³,Lefebvre Patrick²,Sundaram Murali¹,Mato Anthony⁴

Affiliation:

1. Janssen Scientific Affairs, LLC, Horsham, PA, USA

2. Analysis Group Inc., Montréal, Québec, Canada

3. Analysis Group Inc., Menlo Park, CA, USA

4. Memorial Sloan Kettering Cancer Center, New York, NY, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1835851

Reference42 articles.

1. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature

2. An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States

3. Chronic lymphocytic leukaemia

4. National Comprehensive Cancer Network. chronic lymphocytic leukemia/small lymphocytic lymphoma version 1.2021; 2020 [cited 2020 Oct 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

5. TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation;Blood Neoplasia;2024-09

2. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia;Journal of Managed Care & Specialty Pharmacy;2024-05

3. Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors;Leukemia & Lymphoma;2024-02-07

4. Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US;The Oncologist;2024-01-27

5. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia;Patient Preference and Adherence;2023-08